211 related articles for article (PubMed ID: 11081193)
21. PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes.
Cristina C; Díaz-Torga GS; Goya RG; Kakar SS; Perez-Millán MI; Passos VQ; Giannella-Neto D; Bronstein MD; Becu-Villalobos D
Mol Cancer; 2007 Jan; 6():4. PubMed ID: 17222350
[TBL] [Abstract][Full Text] [Related]
22. Dopaminergic inhibition of growth hormone and prolactin release during continuous in vitro perifusion of normal and adenomatous human pituitary.
Lawton NF; Evans AJ; Weller RO
J Neurol Sci; 1981 Feb; 49(2):229-39. PubMed ID: 7217982
[TBL] [Abstract][Full Text] [Related]
23. Pituitary tumour pathogenesis.
Heaney AP
Br Med Bull; 2005; 75-76():81-97. PubMed ID: 16684928
[TBL] [Abstract][Full Text] [Related]
24. Pit-1 gene expression in human lactotroph and somatotroph pituitary adenomas is correlated to D2 receptor gene expression.
Pellegrini-Bouiller I; Morange-Ramos I; Barlier A; Gunz G; Figarella-Branger D; Cortet-Rudelli C; Grisoli F; Jaquet P; Enjalbert A
J Clin Endocrinol Metab; 1996 Sep; 81(9):3390-6. PubMed ID: 8784102
[TBL] [Abstract][Full Text] [Related]
25. Growth hormone-releasing hormone receptor mRNA in acromegalic pituitary tumors.
Lopes MB; Gaylinn BD; Thorner MO; Stoler MH
Am J Pathol; 1997 Jun; 150(6):1885-91. PubMed ID: 9176381
[TBL] [Abstract][Full Text] [Related]
26. A defect in catecholamine neurons in patients with prolactin-secreting pituitary adenoma.
Van Loon GR
Lancet; 1978 Oct; 2(8095):868-71. PubMed ID: 81414
[TBL] [Abstract][Full Text] [Related]
27. [Demonstration of dopaminergic receptors in human pituitary adenomas secreting prolactin].
Bression D; Martres MP; Peillon F
C R Seances Acad Sci D; 1979 Jul; 289(2):133-5. PubMed ID: 117916
[TBL] [Abstract][Full Text] [Related]
28. Effects of the gp130 cytokines ciliary neurotropic factor (CNTF) and interleukin-11 on pituitary cells: CNTF receptors on human pituitary adenomas and stimulation of prolactin and GH secretion in normal rat anterior pituitary aggregate cultures.
Perez Castro C; Carbia Nagashima A; Páez Pereda M; Goldberg V; Chervin A; Carrizo G; Molina H; Renner U; Stalla GK; Arzt E
J Endocrinol; 2001 Jun; 169(3):539-47. PubMed ID: 11375124
[TBL] [Abstract][Full Text] [Related]
29. Biochemical parameters in the anterior pituitary during the course of tumorigenesis induced by diethylstilbestrol treatment.
Piroli G; Lima AE; Díaz-Torga G; De Nicola AF
J Steroid Biochem Mol Biol; 1994 Nov; 51(3-4):183-9. PubMed ID: 7981127
[TBL] [Abstract][Full Text] [Related]
30. Hypothalamic dopamine and catechol oestrogens in rats with spontaneous pituitary tumours.
Prysor-Jones RA; Silverlight JJ; Jenkins JS
J Endocrinol; 1983 Feb; 96(2):347-52. PubMed ID: 6131099
[TBL] [Abstract][Full Text] [Related]
31. Neoplasms of the anterior pituitary.
McCarty KS; Bredesen DE; Vogel FS
Neurosurgery; 1978; 3(1):96-104. PubMed ID: 210418
[No Abstract] [Full Text] [Related]
32. Trophic and neurotrophic factors in human pituitary adenomas (Review).
Spoletini M; Taurone S; Tombolini M; Minni A; Altissimi G; Wierzbicki V; Giangaspero F; Parnigotto PP; Artico M; Bardella L; Agostinelli E; Pastore FS
Int J Oncol; 2017 Oct; 51(4):1014-1024. PubMed ID: 28902350
[TBL] [Abstract][Full Text] [Related]
33. Pathology of excessive production of growth hormone.
Scheithauer BW; Kovacs K; Randall RV; Horvath E; Laws ER
Clin Endocrinol Metab; 1986 Aug; 15(3):655-81. PubMed ID: 3095005
[TBL] [Abstract][Full Text] [Related]
34. Prolactin-secreting pituitary adenoma: occurrence following prenatal exposure to diethylstilbestrol.
Cunningham JR; Gidwani GP; Gupta MS; Duchesneau PM; Schumacher OP
Cleve Clin Q; 1982; 49(4):249-54. PubMed ID: 7168914
[TBL] [Abstract][Full Text] [Related]
35. Estradiol-induced prolactinomas: differential effects on dopamine in posterior pituitary and median eminence.
Burgett RA; Garris PA; Ben-Jonathan N
Brain Res; 1990 Oct; 531(1-2):143-7. PubMed ID: 2289118
[TBL] [Abstract][Full Text] [Related]
36. Targeted overexpression of luteinizing hormone causes ovary-dependent functional adenomas restricted to cells of the Pit-1 lineage.
Mohammad HP; Abbud RA; Parlow AF; Lewin JS; Nilson JH
Endocrinology; 2003 Oct; 144(10):4626-36. PubMed ID: 12960102
[TBL] [Abstract][Full Text] [Related]
37. Galactorrhea and hyperprolactinemia.
Sakiyama R; Quan M
Obstet Gynecol Surv; 1983 Dec; 38(12):689-700. PubMed ID: 6361641
[TBL] [Abstract][Full Text] [Related]
38. Pituitary adenomas associated with hyperprolactinemia: a clinical and immunohistochemical study of 97 patients operated on transsphenoidally.
Randall RV; Scheithauer BW; Laws ER; Abbound CF; Ebersold MJ; Kao PC
Mayo Clin Proc; 1985 Nov; 60(11):753-62. PubMed ID: 3932786
[TBL] [Abstract][Full Text] [Related]
39. Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas.
Luque GM; Perez-Millán MI; Ornstein AM; Cristina C; Becu-Villalobos D
J Pharmacol Exp Ther; 2011 Jun; 337(3):766-74. PubMed ID: 21406548
[TBL] [Abstract][Full Text] [Related]
40. Dopaminergic mechanisms regulating prolactin secretion in patients with prolactin-secreting pituitary adenoma. Long-term studies after selective transsphenoidal surgery.
Barbarino A; De Marinis L; Anile C; Menini E; Merlini G; Maira G
Metabolism; 1982 Nov; 31(11):1100-4. PubMed ID: 6813636
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
